PLI Scheme for Promotion of Domestic Manufacturing of Critical KSMS/Drug Intermediates and APIs

PLI Scheme for Promotion of Domestic Manufacturing of Critical KSMS/Drug Intermediates and APIs

Part of: Prelims and Mains GS-3: Economy

In News: 49 projects approved for 33 critical APIs with an investment of ₹ 3,685 crore under PLI scheme of Bulk Drugs

• Objective: To attain self-reliance in the sector of identified critical drugs

• The scheme has been launched by the Department of Pharmaceuticals for promotion of domestic manufacturing of KSMs/APIs.
• This will be achieved by setting up greenfield plants with minimum domestic value addition 

Do you know? 

• The Indian pharmaceutical industry is the 3rd largest in the world by volume.
• However, India is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. 
• In some specific bulk drugs, the import dependence is 80 to 100%.

News Source: PIB